Capital Asset Advisory Services’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.06M | Buy |
19,928
+1,856
| +10% | +$412K | 0.16% | 78 |
|
|
2025
Q4 | $4.05M | Sell |
18,072
-474
| -3% | -$108K | 0.16% | 77 |
|
|
2025
Q3 | $4.29M | Sell |
18,546
-1,319
| -7% | -$269K | 0.19% | 70 |
|
|
2025
Q2 | $3.77M | Buy |
19,865
+37
| +0.2% | +$6.88K | 0.18% | 74 |
|
|
2025
Q1 | $4.07M | Buy |
19,828
+1,380
| +7% | +$268K | 0.21% | 66 |
|
|
2024
Q4 | $3.34M | Buy |
18,448
+473
| +3% | +$87K | 0.16% | 80 |
|
|
2024
Q3 | $3.47M | Buy |
17,975
+404
| +2% | +$75.4K | 0.17% | 76 |
|
|
2024
Q2 | $2.95M | Sell |
17,571
-1,130
| -6% | -$187K | 0.16% | 81 |
|
|
2024
Q1 | $3.18M | Buy |
18,701
+1,108
| +6% | +$191K | 0.18% | 68 |
|
|
2023
Q4 | $2.73M | Buy |
17,593
+1,100
| +7% | +$160K | 0.17% | 75 |
|
|
2023
Q3 | $2.46M | Buy |
16,493
+2,080
| +14% | +$305K | 0.17% | 74 |
|
|
2023
Q2 | $1.96M | Buy |
14,413
+686
| +5% | +$101K | 0.14% | 85 |
|
|
2023
Q1 | $2.19M | Buy |
13,727
+1,057
| +8% | +$162K | 0.16% | 75 |
|
|
2022
Q4 | $2.09M | Buy |
12,670
+1,455
| +13% | +$223K | 0.17% | 74 |
|
|
2022
Q3 | $1.5M | Buy |
11,215
+946
| +9% | +$136K | 0.2% | 63 |
|
|
2022
Q2 | $1.57M | Buy |
10,269
+21
| +0.2% | +$3.21K | 0.17% | 78 |
|
|
2022
Q1 | $1.66M | Sell |
10,248
-3,132
| -23% | -$455K | 0.18% | 74 |
|
|
2021
Q4 | $1.81M | Buy |
13,380
+650
| +5% | +$76.8K | 0.19% | 71 |
|
|
2021
Q3 | $1.37M | Buy |
12,730
+242
| +2% | +$27.7K | 0.15% | 92 |
|
|
2021
Q2 | $1.41M | Sell |
12,488
-870
| -7% | -$98K | 0.15% | 90 |
|
|
2021
Q1 | $1.45M | Buy |
13,358
+2,556
| +24% | +$273K | 0.22% | 82 |
|
|
2020
Q4 | $1.16M | Buy |
10,802
+1,914
| +22% | +$184K | 0.21% | 83 |
|
|
2020
Q3 | $778K | Sell |
8,888
-679
| -7% | -$63.9K | 0.16% | 115 |
|
|
2020
Q2 | $898K | Buy |
9,567
+246
| +3% | +$21.7K | 0.19% | 100 |
|
|
2020
Q1 | $838K | Buy |
9,321
+1,949
| +26% | +$166K | 0.22% | 82 |
|
|
2019
Q4 | $716K | Buy |
+7,372
| New | +$612K | 0.17% | 114 |
|
|
2018
Q2 | – | Sell |
-2,564
| Closed | -$243K | – | 102 |
|
|
2018
Q1 | $243K | Buy |
2,564
+454
| +22% | +$49.9K | 0.22% | 90 |
|
|
2017
Q4 | $204K | Buy |
+2,110
| New | +$199K | 0.19% | 109 |
|
|
2017
Q1 | – | Sell |
-3,930
| Closed | -$246K | – | 94 |
|
|
2016
Q4 | $246K | Buy |
3,930
+355
| +10% | +$21.7K | 0.21% | 81 |
|
|
2016
Q3 | $225K | Hold |
3,575
| – | – | 0.3% | 58 |
|
|
2016
Q2 | $221K | Buy |
3,575
+65
| +2% | +$3.96K | 0.29% | 58 |
|
|
2016
Q1 | $200K | Buy |
+3,510
| New | +$196K | 0.22% | 75 |
|
Other funds holding ABBV
VCM
VPM
Capital Asset Advisory Services's ABBV Position: Q1 2026 in Review
Capital Asset Advisory Services increased its AbbVie (ABBV) stake by 10% in Q1 2026, buying an estimated $412K and bringing the position to 19,928 shares worth $4.06M. The position accounts for 0.16% of the portfolio, ranked #78.
Capital Asset Advisory Services first reported a position in ABBV in Q1 2016 and has held it in 32 quarters since. The position peaked at $4.29M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Capital Asset Advisory Services held 19,928 shares of AbbVie worth $4.06M as of Q1 2026.
- Capital Asset Advisory Services bought 1,856 AbbVie shares in Q1 2026, an estimated $412K.
- AbbVie made up 0.16% of Capital Asset Advisory Services's portfolio in Q1 2026, its #78 holding.
- Capital Asset Advisory Services first reported a position in AbbVie in Q1 2016 and has held it in 32 quarters since.
- Capital Asset Advisory Services's AbbVie position peaked at $4.29M in Q3 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.